Hexarelin
Potent GH secretagogue; Higher endocrine spillover and desensitization risk
Brief Overview: Hexarelin, also called examorelin, is a synthetic GH secretagogue in the GHRP family. It is known for strong GH release and potential cardiovascular research interest. Evidence lens: The mechanism is stronger than the wellness evidence. It can trigger hormone changes, but long-term body-composition, recovery, or longevity claims remain separate questions. How to read this: if you're new, know that stronger is not automatically better. Once you're past the basics, monitor IGF-1, glucose, edema, blood pressure, prolactin/cortisol context, and loss of effect over time.
- Hexarelin is a synthetic hexapeptide and potent agonist of the growth hormone secretagogue receptor.
- It is chemically related to older GHRPs and is generally considered more intense and more prone to desensitization than gentler options.
- Hexarelin is a potent synthetic GHS-R agonist in the GH-secretagogue family. It is distinct from ipamorelin because it is less selective and has stronger desensitization and off-target endocrine concerns.
- Direct pituitary stimulation: binds GHS-R receptors to release a large GH pulse, widely considered the most potent GHRP for the sheer height of the spike.
- Somatostatin inhibition: suppresses the body's natural brake on GH release.
- Cardioprotection: uniquely also binds CD36 receptors in the heart and blood vessels, and research shows it can protect heart cells from ischemic damage.
- Tissue repair: like other GHRPs it raises IGF-1, aiding muscle protein synthesis and systemic repair.
- Hormonal bleed: more than ipamorelin, it can nudge ACTH, cortisol, and prolactin in some settings.
- It stimulates GH release via GHS-R and may affect ACTH/cortisol/prolactin more than selective secretagogues. Cardiac research signals exist, but that does not make it a cardioprotective therapy. The mechanism here is a plausibility map, not proof of a clinical outcome.
- Heart-failure recovery: data suggests it helps restore cardiac function after myocardial infarction by reducing scar tissue and improving ejection fraction.
- Bone density: particularly effective at increasing bone mineral density, making it a candidate for osteoporosis research.
- Neuroprotection: recent findings explore reduced brain inflammation after traumatic brain injury.
- Fast desensitization: it is more prone to tachyphylaxis (rapidly diminishing response) than ipamorelin or GHRP-2, a practical limit on frequent use.
- Caveat: the cardiovascular literature is mechanistic and small-scale, and does not generalize into an anti-aging or performance therapy.
- Human endocrine data support GH stimulation; Long-term wellness outcomes are not established. Attenuation with repeated exposure is better supported for hexarelin-like agents than for many peptide protocols. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.
Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.
- Protocol 1: Maximum GH Pulse [Research/Experimental]; Route: Subcutaneous (SC); Dose: 100 mcg; Frequency: 2 to 3 times daily; Timing: Fasted (Morning/Night); Duration: 4 to 8 weeks (Max); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 2: Cardiovascular Support (Research) [Research/Experimental]; Route: Subcutaneous (SC); Dose: 50 mcg – 100 mcg; Frequency: Once daily (Nightly); Timing: Nightly; Duration: 2 to 4 weeks; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Cycling/breaks are more defensible here than with ipamorelin because of desensitization concerns. Still, exact 5-on/2-off scheduling is a convention, not a proven optimum. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.
- Time until steady state: roughly 5 to 6.5 hours by half-life math.
- Half-life basis: a human kinetics/disposition study reported an IV half-life of 75.9 +/- 9.3 minutes and subcutaneous bioavailability around 64%, with no clear accumulation across studied subcutaneous doses.
- Beginner translation: If you're new, this does not mean the desired outcome appears in 6 hours. It means drug exposure would approach a plateau if repeated on a constant interval, while the GH pulse itself rises and falls over a shorter window.
- Practical interpretation: Because hexarelin is used for pulse signaling and can desensitize receptors, monitoring response and side effects matters more than chasing constant exposure.
- Comparison note: Hexarelin generally produces a stronger GH pulse and higher desensitization risk than GHRP-2 or ipamorelin. Ipamorelin is usually framed as cleaner, while hexarelin is framed as more forceful.
- Route note: do not generalize intranasal/oral findings across GH secretagogues. Older GHRP-2 and hexarelin data, animal ipamorelin nasal PK, and community sermorelin/CJC nasal-buccal products are different evidence categories.
- Short exposure and strong receptor signaling can coexist. Receptor responsiveness, pituitary reserve, and downstream IGF-1 matter more than half-life alone. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.
- Mechanistic pairings include a GHRH analog such as CJC-1295 without DAC or sermorelin.
- BPC-157 pairings are anecdotal injury-recovery stacks, not controlled evidence.
- Avoid combining with other GH secretagogues or GH without clinician oversight because side effects can compound.
- Stacking with GHRH analogs can amplify GH/IGF-1; Stacking with other appetite/metabolic agents can complicate glucose and fluid effects. Avoid stacking with CJC-DAC unless monitoring is explicit. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.
- Risks include flushing, headache, lethargy, edema, numbness/tingling, glucose disruption, cortisol/prolactin changes, blood-pressure effects, and rapid loss of response with frequent exposure.
- Avoid in active malignancy, uncontrolled diabetes, untreated sleep apnea, pregnancy, or significant cardiovascular instability unless in a formal protocol.
- Main concerns include cortisol/prolactin spillover, edema, numbness, glucose changes, appetite, desensitization, and theoretical cardiac/endocrine complexity. It is not the gentle default GH secretagogue. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.
- Monitor IGF-1, fasting glucose, HbA1c, blood pressure, edema, sleep apnea symptoms, prolactin/cortisol context, and symptom response.
- Cardiovascular research settings may use echocardiography or functional endpoints.
- Track IGF-1, fasting glucose/A1c, edema, sleep apnea symptoms, blood pressure, prolactin/cortisol if symptomatic, and changes in libido or mood. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.
- Hexarelin is not FDA-approved for general human use and is prohibited for athletes under peptide-hormone/secretagogue anti-doping rules.
- It is generally encountered as a research chemical rather than a regulated clinical product.
- Hexarelin is not FDA-approved for anti-aging/body composition. Anti-doping and research-market caveats matter here. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.